Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824875 | 0.92 | MAOA (0.48) | TAAR1KCNA3MAOAMAOBALDH1A1 | |
| SCHEMBL3515342 | 0.78 | TAAR1 (0.41) | TAAR1KCNA3ALDH1A1RECQLSCN4A | |
| SCHEMBL4210725 | 0.77 | TAAR1 (0.44) | TAAR1KCNA3MAOAMAOBALDH1A1 | |
| SCHEMBL226222 | 0.74 | HRH3 (0.43) | MAOBALDH1A1 | |
| SCHEMBL9577039 | 0.73 | KCNA3 (0.43) | TAAR1KCNA3ALDH1A1RECQLTDP1 | |
| SCHEMBL4207677 | 0.73 | ALDH1A1 (0.44) | KCNA3ALDH1A1RECQL | |
| SCHEMBL18291222 | 0.73 | MPO (0.37) | LTA4H | |
| SCHEMBL12453902 | 0.72 | TAAR1 (0.47) | TAAR1KCNA3MAOAMAOBALDH1A1 | |
| SCHEMBL22656555 | 0.72 | TAAR1 (0.42) | TAAR1KCNA3MAOAALDH1A1RECQL | |
| SCHEMBL5227714 | 0.72 | APP (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131502-A1 | Biologically active compounds | QUIBELL MARTIN | 2009-05-21 | — | — | US | claimed |
| WO-2007023281-A2 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2007-03-01 | — | — | WO | claimed |
| US-20090131502-A1 | Biologically active compounds | QUIBELL MARTIN | 2009-05-21 | — | — | US | disclosed |
| WO-2007023281-A2 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131502-A1 | Biologically active compounds | COLGALT1, SOST, COL1A1 | TAAR1 4787/4885KCNA3 3414/4885MAOA 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.